Categoria: 2022

Modern societies are facing health and healthcare challenges as never seen before. The digital world in which we are living today considers digital health interventions such as “internet-delivered” therapy (e-Therapy) or mobile apps as an integrated part of healthcare systems. Digital transformation in health care requires the active involvement of patients as the central part…

Publication History Article published online: 02 June 2022 © 2022. IMIA and Thieme. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted,…

Dear Editor, Immunoglobulin M (IgM) antibodies typically appear in the early stageof infection and have a short maintenance time, so IgM is frequentlyused as a diagnostic criterion for acute or recent disease.1However,unconventional IgM‐specific responses have been described in SARS‐CoV‐2 infection, raising doubts about the use of IgM as a biomarkerfor COVID‐19 and the role of this antibody in immunity to SARS‐CoV‐2

Introdução: a pandemia do COVID-19 provocou mudanças importantes no uso das tecnologias e da comunicação digital. É necessário compreendermos melhor as práticas de enfrentamento da pandemia pela população através da apropriação de informações veiculadas pelas mídias sociais. Espera-se que este trabalho auxilie na formulação de estratégias de educação em saúde na ESF. O objetivo deste…

Abstract: We evaluated the longitudinal dynamics of antibody response to the SARS-CoV-2 vaccine CoronaVac and the effect of a booster dose of BNT162b2 vaccine. We found a robust antibody response after the second dose of CoronaVac that wanes over time. The response was recovered by BNT162b2, which boosted anti-spike antibody titers.

Abstract: CoronaVac was the first vaccine approved in Brazil for use in healthcare workers (HCWs). However, there is limited information about it, with little long-term evidence on post-vaccination antibody persistence. This study evaluated the antibody response to SARS-CoV-2 in 1237 HCWs after the first (1D), second dose (2D), and 6 months postvaccination (6mA2D) with CoronaVac. The seropositivity was 88% at 1D, increasing to 99.8% at 2D, but decreasing to 97.9% at 6mA2D, which was also observed at the analyzed antibody levels. Interestingly, the levels in females were higher than males, and we found a positive correlation with previous SARS-CoV-2 infection. Participants with comorbidities had lower levels suggesting the need to monitor for a potential booster dose. Our findings suggest that CoronaVac induced a robust antibody response that wanes significantly over time. Further longitudinal studies are needed to identify whether the antibodies will decline or plateau at a lower level.

Resumo Paralelamente à pandemia de covid-19, a Organização Mundial da Saúde alerta para uma infodemia de fake news relacionadas à doença. Objetiva-se, neste trabalho, conhecer a dimensão do fenômeno e alguns caminhos já identificados pela ciência para enfrentá-lo. Trata-se de uma revisão integrativa da literatura, realizada nas bases Scopus/Elsevier e Medline/PubMed, que incluiu 23 artigos.…

Publicação de 2022. Anais — WebMedia, Workshop de Ferramentas e Aplicações (WFA) e Prêmio LF. DOI: 10.5753/webmedia_estendido.2022.227224.

The COVID-19 pandemic of the last two years has affected the lives of many individuals, especially the most vulnerable and at-risk population groups, e.g., older adults. While social distancing and isolation are shown to be effective at decreasing the transmission of the virus, these actions have also increased loneliness and social isolation. To combat social…